



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

HAMNO

| | | | |
|--------------------|---|-------|---------|
| Cat. No.: | HY-111285 | | |
| CAS No.: | 138736-73-9 | | |
| Molecular Formula: | C ₁₇ H ₁₃ NO ₂ | | |
| Molecular Weight: | 263.29 | | |
| Target: | Others | | |
| Pathway: | Others | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 2 years |
| | | -20°C | 1 year |



SOLVENT & SOLUBILITY

| | | | | | | |
|---|--|---|-----------|------------|------------|-------|
| In Vitro | DMSO : 50 mg/mL (189.90 mM; Need ultrasonic) | | | | | |
| | Preparing Stock Solutions | <div><div>Solvent</div><div>Concentration</div></div> | Mass | 1 mg | 5 mg | 10 mg |
| | | | | | | |
| | | 1 mM | 3.7981 mL | 18.9905 mL | 37.9809 mL | |
| | | 5 mM | 0.7596 mL | 3.7981 mL | 7.5962 mL | |
| | | 10 mM | 0.3798 mL | 1.8990 mL | 3.7981 mL | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) | | | | | |
| | Solubility: 2.5 mg/mL (9.50 mM); Suspended solution; Need ultrasonic | | | | | |

BIOLOGICAL ACTIVITY

| | |
|---------------------------|---|
| Description | HAMNO is a novel protein interaction inhibitor of replication protein A (RPA). |
| IC ₅₀ & Target | RPA ^[1] |
| In Vitro | <p>HAMNO is a novel protein interaction inhibitor of replication protein A (RPA). RPA is involved in the ATR/Chk1 pathway. HAMNO alone inhibits colony formation in both HNSCC cell lines in the low micromolar range. HAMNO combined with etoposide significantly inhibits colony formation to a greater degree than HAMNO alone. After UMSCC38 cells are exposed to HAMNO, increased pan-nuclear γ-H2AX staining occurs in a dose dependent manner. Cancer derived UMSCC38 cells, as well as another cancer cell line, UMSCC11B, have prominent γ-H2AX staining, particularly after incubation with 20 μM HAMNO. Both UMSCC38 and OKF4 cells present increased γ-H2AX staining after addition of HAMNO, with the greatest increase in signal occurring in S-phase^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> |

In Vivo

In mice, HAMNO slows the progression of UMSCC11B tumors. Ser33 of RPA32, an ATR substrate, is highly phosphorylated after two hours of treatment with 20 μ M of etoposide, which is reduced with the addition of 2 μ M HAMNO, and is nearly absent at higher concentrations, demonstrating an in vivo effect of HAMNO as an inhibitor of RPA32 phosphorylation by ATR [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay [1]

Cell cycle assessment and γ -H2AX staining are monitored in UMSCC38 and OKF4 cells after 2 h incubation with HAMNO (2, 20, 50 μ M) and fixed in 70% ethanol overnight. Cells are washed with PBS and incubated overnight in PBS containing 1% BSA, 10% goat serum and PS139-H2AX antibodies, washed and incubated in goat anti-mouse Alexa Fluor 647 antibody for 30 min at room temperature. Cells are incubated in 50 μ g/mL propidium iodide and 100 μ g/mL RNase A for 30 min, and 10,000 cells per sample are analyzed [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration [1]

Athymic nude mice are used in this study. UMSCC38 and UMSCC11B cells are implanted into 6-week-old female mice by a single subcutaneous injection of tumor cells (2 to 6×10^5 cells in 100 mL of sterile PBS). The growth rates of tumors are determined by daily monitoring of tumor volume with vernier calipers [tumor volume = $1/2(\text{length} \times \text{width}^2)$]. Once the tumor size reaches 50 mm³, etoposide (10 mg/kg mouse) and HAMNO (2 mg/kg) are administered intraperitoneally every day for 3 days. Tumor size is monitored daily and the volume of the tumor is compared among all experimental groups. At least three mice are used per group [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Glanzer JG, et al. RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res. 2014 Sep 15;74(18):5165-72.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA